Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation. (1st March 2022)

• Record Type: Journal Article
• Authors: Song, Geng; Zhang, Fei‐Fei; Cheng, Huai‐Dong
• Is Part Of: Australasian journal of dermatology. Volume 63:Number 2(2022)
• Page Start: 217
• Page End: 221
• Publication Date: 2022-03-01
• Subjects: camrelizumab -- reactive cutaneous capillary endothelial proliferation -- thalidomide; Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.13812
• Languages: English
• ISSNs: 0004-8380

Abstract

ABSTRACT: Objectives: The study evaluated the efficacy of thalidomide in prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation (RCCEP). Methods: In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset time, severity of RCCEP and the adverse effect of thalidomide were analysed. Results: A total of 19 patients were enrolled. The incidence of RCCEP in thalidomide group (2/9, 22.2%) was significantly lower than that in camrelizumab group (8/10, 80%). The median onset time of RCCEP was 5 weeks and 4 weeks respectively. The adverse events of thalidomide were mild, and no treatment‐associated interruption was observed. Conclusions: Thalidomide showed a promising in prevention of the RCCEP in patients receiving camrelizumab therapy with an acceptable safety profile.